ENTERA BIO LTD. Operating Lease Cost
ENTERA BIO LTD. (ENTX) reported Operating Lease Cost of $240.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-27
- ENTERA BIO LTD. operating lease, cost for fiscal 2025 was $240.00K, a 21.21% increase from fiscal 2024.
- ENTERA BIO LTD. operating lease, cost for fiscal 2024 was $198.00K, a 1.02% increase from fiscal 2023.
- ENTERA BIO LTD. operating lease, cost for fiscal 2023 was $196.00K, a 0.51% decline from fiscal 2022.
- ENTERA BIO LTD. operating lease, cost for fiscal 2022 was $197.00K, a 8.80% decline from fiscal 2021.
| Period end | Operating Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $240.00K 10-K · filed 2026-03-27 |
| 2024-12-31 | $198.00K 10-K · filed 2026-03-27 |
| 2023-12-31 | $196.00K 10-K · filed 2025-03-28 |
| 2022-12-31 | $197.00K 10-K · filed 2024-03-08 |
| 2021-12-31 | $216.00K 10-K · filed 2023-03-31 |
| 2020-12-31 | $180.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |